YALE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1701-10-09

Employees: 10K

Market Cap: -

Website: http://www.yale.edu

Clinical Trials

Ketamine in Borderline Personality Disorder

Phase 2

Terminated

Conditions: Borderline Personality Disorder

Interventions: Drug: Midazolam
Drug: Ketamine

First Posted Date: 2018-01-10

Last Posted Date: 2023-06-26

Lead Sponsor: Yale University

Target Recruit Count: 22

Registration Number: NCT03395314

Locations: 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States
🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States

Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)

Phase 2

Completed

Conditions: Cannabis Use Disorder

Interventions: Drug: PF 04457845
Drug: Placebo Oral Tablet

First Posted Date: 2017-12-29

Last Posted Date: 2024-02-14

Lead Sponsor: Yale University

Target Recruit Count: 228

Registration Number: NCT03386487

Locations: 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States
🇺🇸
Columbia University Medical College / New York State Psychiatric Institute, New York, New York, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

and more 1 locations

Utilizing Ultrasound for Residents as an Aid in Epidural Placement

Not Applicable

Withdrawn

Conditions: Epidural Placement

Interventions: Device: Ultrasound Guided Epidural
Procedure: Standard Epidural

First Posted Date: 2017-12-19

Last Posted Date: 2019-01-10

Lead Sponsor: Yale University

Registration Number: NCT03378492

A Trial of a Multi-component Individualized Telephone-based Support Intervention for Adult-child Caregivers Caring for Parents With Dementia

Not Applicable

Withdrawn

Conditions: Dementia

Interventions: Other: Usual Care
Behavioral: HEART

First Posted Date: 2017-12-19

Last Posted Date: 2021-04-20

Lead Sponsor: Yale University

Registration Number: NCT03378050

Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone

Not Applicable

Completed

Conditions: Multiple Myeloma

Interventions: Procedure: Guided Lesion Biopsies
Procedure: Standard Lesion Biopsies

First Posted Date: 2017-12-18

Last Posted Date: 2022-02-24

Lead Sponsor: Yale University

Target Recruit Count: 28

Registration Number: NCT03375567

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States

Targeting Self-regulatory Deficits Through Cognitive Remediation Intervention

Not Applicable

Completed

Conditions: Drug Use Disorders

Interventions: Behavioral: TAU plus Control Tasks
Behavioral: TAU plus Cognitive Remediation Program

First Posted Date: 2017-12-14

Last Posted Date: 2021-01-08

Lead Sponsor: Yale University

Target Recruit Count: 46

Registration Number: NCT03373240

Locations: 🇺🇸
Substance Abuse Treatment Center (SATU), New Haven, Connecticut, United States

Home vs. Office Foley Catheter Removal in Women With Voiding Difficulty Following Pelvic Reconstructive Surgery

Not Applicable

Completed

Conditions: Voiding Disorders

Interventions: Procedure: Foley catheter removal

First Posted Date: 2017-12-14

Last Posted Date: 2022-08-29

Lead Sponsor: Yale University

Target Recruit Count: 78

Registration Number: NCT03373773

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

The PrISICE Clinical Trial (Pre-Implantation Screening and Investigation on the Cryopreservation of Embryos)

Not Applicable

Terminated

Conditions: Infertility

Interventions: Procedure: Trophectoderm biopsy
Procedure: Cryopreservation
Procedure: Embryo Transfer

First Posted Date: 2017-12-13

Last Posted Date: 2022-10-03

Lead Sponsor: Yale University

Target Recruit Count: 32

Registration Number: NCT03371745

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Translating Neuroprediction Into Precision Medicine Via Brain Priming

Phase 2

Terminated

Conditions: Autism Spectrum Disorder

Interventions: Drug: Oxytocin
Behavioral: Pivotal Response Treatment
Drug: Placebo

First Posted Date: 2017-12-12

Last Posted Date: 2022-08-09

Lead Sponsor: Yale University

Target Recruit Count: 5

Registration Number: NCT03370510

Locations: 🇺🇸
Yale School of Medicine, New Haven, Connecticut, United States

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

Phase 1

Completed

Conditions: Bipolar Disorder
Depressive Disorder, Major
Post Traumatic Stress Disorder

Interventions: Drug: Ketamine
Drug: Placebo
Drug: Perampanel

First Posted Date: 2017-12-08

Last Posted Date: 2024-05-08

Lead Sponsor: Yale University

Target Recruit Count: 13

Registration Number: NCT03367533

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy